{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:30:57Z","timestamp":1760239857191,"version":"build-2065373602"},"reference-count":59,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.hoc.2020.08.006","type":"journal-article","created":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T06:34:13Z","timestamp":1603262053000},"page":"1161-1175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Solid Organ Transplantation"],"prefix":"10.1016","volume":"34","author":[{"given":"Susan","family":"Bal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather J.","family":"Landau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.hoc.2020.08.006_bib1","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/blood-2004-01-0390","article-title":"Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation","volume":"104","author":"Dispenzieri","year":"2004","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.hoc.2020.08.006_bib2","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A\u00a0European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.hoc.2020.08.006_bib3","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1182\/blood-2010-05-286567","article-title":"The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis","volume":"116","author":"Palladini","year":"2010","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.hoc.2020.08.006_bib4","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1161\/01.CIR.0000068314.02595.B2","article-title":"Serum N-terminal pro\u2013brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis","volume":"107","author":"Palladini","year":"2003","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.hoc.2020.08.006_bib5","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A\u00a0staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2020.08.006_bib6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ajh.23898","article-title":"Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis: Response Kinetics in AL Amyloidosis","volume":"90","author":"Kaufman","year":"2015","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.hoc.2020.08.006_bib7","first-page":"68","article-title":"High-dose therapy and autologous transplantation in amyloidosis-AL","volume":"78","author":"Majolino","year":"1993","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.hoc.2020.08.006_bib8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7326\/0003-4819-140-2-200401200-00008","article-title":"High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study","volume":"140","author":"Skinner","year":"2004","journal-title":"Ann Intern Med"},{"issue":"16","key":"10.1016\/j.hoc.2020.08.006_bib9","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1182\/blood-2011-01-330738","article-title":"Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients","volume":"118","author":"Cibeira","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2020.08.006_bib10","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/bjh.16096","article-title":"Ten-year survivors in AL amyloidosis: characteristics and treatment pattern","volume":"187","author":"Muchtar","year":"2019","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2020.08.006_bib11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1080\/10428190701684518","article-title":"Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis","volume":"49","author":"Gertz","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.hoc.2020.08.006_bib12","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1159\/000508262","article-title":"Solid organ transplantation in amyloidosis","volume":"143","author":"Theodorakakou","year":"2020","journal-title":"Acta Haematol"},{"issue":"6","key":"10.1016\/j.hoc.2020.08.006_bib13","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.nephro.2012.06.004","article-title":"Preemptive kidney transplantation: has it come of age?","volume":"8","author":"Huang","year":"2012","journal-title":"N\u00e9phrol Th\u00e9r"},{"issue":"7","key":"10.1016\/j.hoc.2020.08.006_bib14","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1182\/blood.V88.7.2801.bloodjournal8872801","article-title":"Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients","volume":"88","author":"Comenzo","year":"1996","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.hoc.2020.08.006_bib15","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1182\/blood-2015-08-662726","article-title":"Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience","volume":"126","author":"Sanchorawala","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2020.08.006_bib16","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.bbmt.2015.04.001","article-title":"Induction therapy with bortezomib followed by bortezomib-high dose melphalan and stem cell transplantation for light chain amyloidosis: results of a prospective clinical trial","volume":"21","author":"Sanchorawala","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.hoc.2020.08.006_bib17","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1182\/blood-2007-02-076034","article-title":"Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis","volume":"110","author":"Palladini","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2020.08.006_bib18","first-page":"165","article-title":"Heart transplantation for cardiac amyloidosis: successful one-year outcome despite recurrence of the disease","volume":"7","author":"Conner","year":"1988","journal-title":"J\u00a0Heart Transplant"},{"issue":"6962","key":"10.1016\/j.hoc.2020.08.006_bib19","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1136\/bmj.309.6962.1135","article-title":"Grand Rounds - Hammersmith Hospital: Cardiac transplantation for AL amyloidosis","volume":"309","author":"Hall","year":"1994","journal-title":"BMJ"},{"issue":"5 Suppl","key":"10.1016\/j.hoc.2020.08.006_bib20","first-page":"III338","article-title":"Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation. Follow-up results of a multicenter survey","volume":"84","author":"Hosenpud","year":"1991","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.hoc.2020.08.006_bib21","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0002-9149(99)80214-8","article-title":"Recurrence of primary (AL) amyloidosis in a transplanted heart with four-year survival","volume":"76","author":"Dubrey","year":"1995","journal-title":"Am J Cardiol"},{"issue":"11","key":"10.1016\/j.hoc.2020.08.006_bib22","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.healun.2004.08.025","article-title":"Outcome of heart transplantation in patients with amyloid cardiomyopathy","volume":"24","author":"Kpodonu","year":"2005","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"3","key":"10.1016\/j.hoc.2020.08.006_bib23","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1182\/blood-2005-08-3253","article-title":"Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis","volume":"107","author":"Gillmore","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2020.08.006_bib24","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.tp.0000255567.80203.bd","article-title":"Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure","volume":"83","author":"Maurer","year":"2007","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.hoc.2020.08.006_bib25","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1111\/j.1600-6143.2009.02643.x","article-title":"Outcomes of heart transplantation for cardiac amyloidosis: subanalysis of the spanish registry for heart transplantation","volume":"9","author":"Roig","year":"2009","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.hoc.2020.08.006_bib26","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.healun.2008.05.016","article-title":"Autologous stem cell transplant after heart transplant for light chain (AL) amyloid cardiomyopathy","volume":"27","author":"Lacy","year":"2008","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"9","key":"10.1016\/j.hoc.2020.08.006_bib27","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.acvd.2008.06.018","article-title":"Heart transplantation in systemic (AL) amyloidosis: A retrospective study of eight French patients","volume":"101","author":"Mignot","year":"2008","journal-title":"Arch Cardiovasc Dis"},{"issue":"5","key":"10.1016\/j.hoc.2020.08.006_bib28","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.healun.2017.11.015","article-title":"Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era","volume":"37","author":"Kristen","year":"2018","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"8","key":"10.1016\/j.hoc.2020.08.006_bib29","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1097\/TP.0b013e3181f10edb","article-title":"Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure","volume":"90","author":"Dey","year":"2010","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.hoc.2020.08.006_bib30","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.healun.2013.09.004","article-title":"Predictors of survival to orthotopic heart transplant in patients with light chain amyloidosis","volume":"33","author":"Gray Gilstrap","year":"2014","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"2","key":"10.1016\/j.hoc.2020.08.006_bib31","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood-2006-07-032987","article-title":"The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis","volume":"109","author":"Dispenzieri","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2020.08.006_bib32","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood-2006-07-030544","article-title":"Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial","volume":"109","author":"Sanchorawala","year":"2007","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2020.08.006_bib33","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3324\/haematol.11325","article-title":"Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone","volume":"92","author":"Kastritis","year":"2007","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.hoc.2020.08.006_bib34","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3324\/haematol.11627","article-title":"Efficacy of bortezomib in systemic AL amyloidosis with relapsed\/refractory clonal disease","volume":"93","author":"Wechalekar","year":"2008","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.hoc.2020.08.006_bib35","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1111\/j.1600-6143.2010.03227.x","article-title":"Solid organ transplantation in AL amyloidosis: transplantation in AL amyloidosis","volume":"10","author":"Sattianayagam","year":"2010","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.hoc.2020.08.006_bib36","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/ajt.13025","article-title":"Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era: heart transplant for amyloid cardiomyopathy","volume":"15","author":"Davis","year":"2015","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1016\/j.hoc.2020.08.006_bib37","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1093\/ndt\/gfp201","article-title":"Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney","volume":"24","author":"Gertz","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"10.1016\/j.hoc.2020.08.006_bib38","doi-asserted-by":"crossref","first-page":"E458","DOI":"10.1002\/ajh.24464","article-title":"Validation of new renal staging system in AL amyloidosis treated with high dose melphalan and stem cell transplantation","volume":"91","author":"Havasi","year":"2016","journal-title":"Am J Hematol"},{"issue":"36","key":"10.1016\/j.hoc.2020.08.006_bib39","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2020.08.006_bib40","doi-asserted-by":"crossref","first-page":"E129","DOI":"10.1002\/ajh.25066","article-title":"Predictive value of the new renal response criteria in AL amyloidosis treated with high dose melphalan and stem cell transplantation","volume":"93","author":"Havasi","year":"2018","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.hoc.2020.08.006_bib41","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/00007890-198612000-00005","article-title":"Renal transplantation in 45 patients with amyloidosis","volume":"42","author":"Pasternack","year":"1986","journal-title":"Transplantation"},{"issue":"7","key":"10.1016\/j.hoc.2020.08.006_bib42","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1111\/j.1600-6143.2005.00920.x","article-title":"Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement","volume":"5","author":"Leung","year":"2005","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.hoc.2020.08.006_bib43","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1093\/ndt\/gfr067","article-title":"Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation","volume":"26","author":"Herrmann","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.hoc.2020.08.006_bib44","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/bjh.16246","article-title":"Kidney transplantation in AL Amyloidosis: is it time to maximize access?","volume":"188","author":"Sathick","year":"2020","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2020.08.006_bib45","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.kint.2018.09.021","article-title":"Long-term outcome of kidney transplantation in AL amyloidosis","volume":"95","author":"Angel-Korman","year":"2019","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.hoc.2020.08.006_bib46","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.kint.2018.11.003","article-title":"Improved outcomes for kidney transplantation in AL amyloidosis: impact on practice","volume":"95","author":"Nuvolone","year":"2019","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.hoc.2020.08.006_bib47","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1182\/blood.V68.1.220.220","article-title":"Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases","volume":"68","author":"Kyle","year":"1986","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2020.08.006_bib48","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1111\/j.1572-0241.1998.00628.x","article-title":"Primary amyloidosis with spontaneous splenic rupture, cholestasis, and liver failure treated with emergency liver transplantation","volume":"93","author":"Sandberg-Gertz\u00e9n","year":"1998","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"10.1016\/j.hoc.2020.08.006_bib49","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.2169\/internalmedicine.55.6675","article-title":"Liver transplantation is a potential treatment option for systemic light chain amyloidosis patients with dominant hepatic involvement: a case report and analytical review of the literature","volume":"55","author":"Ueno","year":"2016","journal-title":"Intern Med"},{"issue":"4","key":"10.1016\/j.hoc.2020.08.006_bib50","first-page":"592","article-title":"Liver transplantation followed by autologous stem cell transplantation for acute liver failure caused by AL amyloidosis. Case report and review of the literature","volume":"15","author":"Elnegouly","year":"2016","journal-title":"Ann Hepatol"},{"issue":"1","key":"10.1016\/j.hoc.2020.08.006_bib51","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2020.08.006_bib52","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/bmt.2016.222","article-title":"Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis","volume":"51","author":"Landgren","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.hoc.2020.08.006_bib53","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41408-018-0086-3","article-title":"Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis","volume":"8","author":"Kastritis","year":"2018","journal-title":"Blood Cancer J"},{"issue":"Supplement_1","key":"10.1016\/j.hoc.2020.08.006_bib54","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1182\/blood-2019-131863","article-title":"The use of next generation gene sequencing to measure minimal residual disease in patients with AL amyloidosis and low plasma cell burden: a feasibility study","volume":"134","author":"Sarosiek","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2020.08.006_bib55","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/13506129.2019.1666709","article-title":"Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis","volume":"27","author":"Muchtar","year":"2020","journal-title":"Amyloid"},{"issue":"8","key":"10.1016\/j.hoc.2020.08.006_bib56","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.mayocp.2015.06.009","article-title":"Treatment of immunoglobulin light chain amyloidosis: mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement","volume":"90","author":"Dispenzieri","year":"2015","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"10.1016\/j.hoc.2020.08.006_bib57","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.healun.2003.08.027","article-title":"Cardiac transplantation for amyloid heart disease: the United Kingdom experience","volume":"23","author":"Dubrey","year":"2004","journal-title":"J Heart Lung Transplant"},{"issue":"2","key":"10.1016\/j.hoc.2020.08.006_bib58","doi-asserted-by":"crossref","first-page":"380","DOI":"10.5500\/wjt.v6.i2.380","article-title":"Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience","volume":"6","author":"Grogan","year":"2016","journal-title":"World J Transplant"},{"issue":"5","key":"10.1016\/j.hoc.2020.08.006_bib59","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41408-020-0325-2","article-title":"The impact and importance of achieving a complete haematological response prior to renal transplantation in AL amyloidosis","volume":"10","author":"Cohen","year":"2020","journal-title":"Blood Cancer J."}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820301015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820301015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:15:08Z","timestamp":1760184908000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858820301015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0889858820301015"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2020.08.006","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Solid Organ Transplantation","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2020.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}